PapersPMID:37701187
The effect of spirulina sauce on glycemic index, lipid profile, and oxidative stress in type 2 diabetic patients: A randomized double-blind clinical trial.
- findings
- 6
- compound
- 1
- endpoints
- 6
- Study, every finding
- RCT
- Dose studied, every finding
- 2 g Arthrospira platensis per day in a 20 g sauce sachet, 2 months
- Population, every finding
- Adults aged 30-65 with type 2 diabetes, all on an isocaloric diabetic diet; spirulina sauce versus placebo sauce, other sauce ingredients identical
No finding here moved its endpoint.
What did not
How to read these marks →“Results showed no significant change in HbA1c (mean difference (MD): 0.13%, 95% confidence (CI) −.083 to 0.57, p =.75), FBG (MD: −15.3 mg/dL, 95% CI −44.2 to 13.60, p =.26), insulin (MD: −1.46 μIU/mL, 95% CI −4.0 to 1.09, p =.28), and HOMA‐IR (MD: −0.35, 95% CI −2.0 to 1.32, p =.68) between the two groups.”
- No detected effect on fasting blood glucose
moderatereplicated ×2
- Effect
- −15.3 mean difference, 95% CI −44.2 to 13.6
- Interests
- Industry funded
- No detected effect on HOMA-IR
moderate
- Effect
- −0.35 mean difference, 95% CI −2 to 1.32
- Interests
- Industry funded
- No detected effect on fat mass
moderate
“Body composition characteristics, including fat mass, fat free mass, and total body water did not change statistically significantly between the two groups (Table 4).”
- Interests
- Industry funded
“Weight and BMI did not show significant changes between the two groups (p =.69 and.68, respectively).”
- No detected effect on body mass index
moderatereplicated ×2
- Interests
- Industry funded
- No detected effect on body mass
moderatereplicated ×2
- Interests
- Industry funded
- No detected effect on HDL cholesterol
moderatereplicated ×3
“HDL (MD: −1.9 mg/dL, 95% CI −6.15 to 2.35, p =.32) levels did not change significantly between the two groups (Table 3).”
- Effect
- −1.9 mean difference, 95% CI −6.15 to 2.35
- Interests
- Industry funded
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Patients with type 2 diabetes, both genders, age 30-65 years, Shiraz, Iran
- Participants
- 40
- Comparator
- placebo
- Duration
- 61 days
- Endpoints measured
- 55